ArticleSignal transduction and targeted therapy2026

Potent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation.

Jiang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.